



# Kent Academic Repository

Smith, Samuel Andrew, Micklewright, Dominic, Winter, Samantha L. and Mauger, Alexis R. (2020) *Muscle pain induced by hypertonic saline in the knee extensors decreases single-limb isometric time to task failure*. *European journal of applied physiology* . ISSN 1439-6327.

## Downloaded from

<https://kar.kent.ac.uk/81745/> The University of Kent's Academic Repository KAR

## The version of record is available from

<https://doi.org/10.1007/s00421-020-04425-2>

## This document version

Author's Accepted Manuscript

## DOI for this version

## Licence for this version

UNSPECIFIED

## Additional information

## Versions of research works

### Versions of Record

If this version is the version of record, it is the same as the published version available on the publisher's web site. Cite as the published version.

### Author Accepted Manuscripts

If this document is identified as the Author Accepted Manuscript it is the version after peer review but before type setting, copy editing or publisher branding. Cite as Surname, Initial. (Year) 'Title of article'. To be published in **Title of Journal** , Volume and issue numbers [peer-reviewed accepted version]. Available at: DOI or URL (Accessed: date).

### Enquiries

If you have questions about this document contact [ResearchSupport@kent.ac.uk](mailto:ResearchSupport@kent.ac.uk). Please include the URL of the record in KAR. If you believe that your, or a third party's rights have been compromised through this document please see our [Take Down policy](https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies) (available from <https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies>).

1           **MUSCLE PAIN INDUCED BY HYPERTONIC SALINE IN THE KNEE**  
2           **EXTENSORS DECREASES SINGLE-LIMB ISOMETRIC TIME TO TASK**  
3                           **FAILURE**

4  
5           Samuel A Smith<sup>1</sup>, Dominic Micklewright<sup>2</sup>, Samantha L Winter<sup>1</sup>, Alexis R Mauger<sup>1</sup>

6  
7           <sup>1</sup>Endurance Research Group, School of Sport and Exercise Sciences, University of Kent,  
8           Chatham Maritime, (UK).

9           <sup>2</sup>School of Sport, Rehabilitation and Exercise Sciences, University of Essex, Wivenhoe Park,  
10          Colchester, (UK).

11  
12          **Correspondence to:** Alexis (Lex) Mauger, School of Sport and Exercise Sciences,  
13          University of Kent, ME4 4AG, United Kingdom  
14          Tel: +44 (0)1634 888997  
15          Email: lex.mauger@gmail.com  
16          Institutional URL: <https://www.kent.ac.uk/sportsciences/people/profiles/mauger-lex.html>

17  
18          **Author ORCID**

19          Samuel A Smith: 0000-0002-0833-0878

20          Dominic Micklewright: 0000-0002-7519-3252

21          Samantha L Winter: 0000-0001-7450-1105

22          Alexis R Mauger: 0000-0001-6685-5800

26 *Acknowledgements*

27 Ausra Galdiauskaite, Gemma Gow and Nadia McMillan for their dedication and assistance  
28 with data collection. Ryan Norbury for assistance with figure preparation.

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51 **DECLARATIONS**

52 *Funding*

53 No funding sources were provided for the present study. This research project did not receive  
54 any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

55

56 *Conflict of Interest*

57 The authors declare that they have no conflict of interest.

58

59 *Ethical Approval*

60 The School of Sport and Exercises (University of Kent) Research Ethics Advisory Group  
61 (Prop 84\_2016\_17) approved all procedures and protocols in accordance with the Declaration  
62 of Helsinki.

63

64 *Consent to Participate*

65 Written informed consent was gained from the participants prior to participation.

66

67 *Consent for Publication*

68 N/A

69

70 *Availability of Data and Materials*

71 The datasets generated during and/or analysed during the current study are available from the  
72 corresponding author on reasonable request.

73

74 *Code Availability*

75 Custom code written in MATLAB R2018a (The MathWorks, Massachusetts, USA).

76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100

*Author Contributions*

ARM was responsible for the conception of the study. SAS, DM and ARM were responsible for the design of the work. SAS and ARM were responsible for data acquisition. All experiments were performed in the Medway Park Exercise Physiology Laboratory, School of Sport and Exercise Sciences, University of Kent. SAS, DM, SLW, and ARM were responsible for data analysis and interpretation. SAS was responsible for drafting the manuscript. SAS, DM, SLW and ARM were responsible for critically revising and editing intellectual content. All persons designated as authors qualify for authorship, and all those who qualify for authorship are listed. All authors have read and approved the final version of the manuscript submitted for publication and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

101 **ABSTRACT**

102 **Purpose:** Increased nociceptive activity and the experience of exercise-induced pain (EIP)  
103 may contribute to fatigue during endurance exercise. To investigate this, a pain model that  
104 produces pain similar to EIP and decouples its' relationship to exercise intensity is required.  
105 This study 1) compared the quality of pain caused by a hypertonic saline injection into the  
106 vastus lateralis in resting and exercise conditions, and 2) investigated whether this pain  
107 contributes to changes in time to task failure. **Methods:** On separate days, eighteen  
108 participants completed a time to task failure at 20% maximal voluntary torque (MVT), a  
109 resting hypertonic saline intramuscular injection, and in a further three visits a time to task  
110 failure at 10% MVT following injection of isotonic saline, hypertonic saline or a control (no  
111 injection). **Results:** In a subset of eligible participants (n = 12), the hypertonic saline  
112 combined with 10% MVT produced a qualitative experience of pain (assessed by the McGill  
113 Pain Questionnaire) that felt similar to EIP. 10% MVT with hypertonic saline significantly  
114 elevated pain intensity in the first 20% of the time to task failure and caused a significantly ( $P$   
115  $< 0.05$ ) shorter time to task failure ( $448 \pm 240$  s) compared with the isotonic saline ( $605 \pm$   
116  $285$  s) and control ( $514 \pm 197$  s) conditions. **Conclusion:** These findings demonstrate that  
117 hypertonic saline increases the intensity of pain during exercise, which results in a faster  
118 occurrence of exercise-induced fatigue. These results provide important evidence supporting  
119 pain as a limiting factor in endurance performance.

120

121 **Key words:** Endurance, exercise-induced pain, fatigue, hypertonic saline, isometric,

122 nociception

123

124

125

126 **Abbreviations**

<b>ANOVA</b>	Analysis of variance
<b>EIP</b>	Exercise-induced pain
<b>HR</b>	Heart rate
<b>HYP</b>	Hypertonic saline
<b>ISO</b>	Isotonic saline
<b>MPQ</b>	McGill Pain Questionnaire
<b>MVC</b>	Maximal voluntary contraction
<b>MVT</b>	Maximal voluntary torque
<b>PANAS</b>	Positive and Negative Affect Schedule
<b>PRI(T)</b>	Pain rating index (total)
<b>RF</b>	Rectus femoris
<b>RPE</b>	Rating of perceived exertion
<b>SD</b>	Standard deviation
<b>sEMG</b>	Surface electromyography
<b>SRI</b>	Subclass rating index
<b>VAS</b>	Visual analogue scale
<b>VL</b>	Vastus lateralis
<b>VM</b>	Vastus medialis

127

128

129

130

131

132

133 **INTRODUCTION**

134 Intense and prolonged muscle contractions result in acute pain proportional to the intensity  
135 and duration of exercise (Cook et al. 1997). This ‘exercise-induced pain’ (EIP) arises from  
136 the sensitisation and activation of ascending group III and IV nociceptive afferents in  
137 response to the accumulation of endogenous algesics and increases in noxious and  
138 mechanical pressure within the contracting skeletal musculature (O’Connor and Cook 1999).  
139 The experience of EIP is often accompanied by fatigue (Pollak et al. 2014), which is defined  
140 as an exercise-induced reduction in the capacity to produce muscle force or power (Bigland-  
141 Ritchie and Wood 1984). This association has led to the suggestion that EIP may accelerate  
142 fatigue development during intense and prolonged exercise (Mauger 2014).

143

144 In support of this notion, the stimulation of muscle nociceptors and increased muscle afferent  
145 activity has demonstrated significant reductions in voluntary activation of the elbow flexors  
146 (Kennedy et al. 2013) and maximal voluntary force of the knee extensors (Graven-Nielsen et  
147 al. 2002). Furthermore, partial blockade of group III and IV muscle afferents at the spinal  
148 level results in the attenuation of perceived fatigue, and increases central motor drive (Amann  
149 et al. 2009). Based on these findings, it is suggested that the increased activation of group III  
150 and IV afferents inhibit central motor drive and the ability to recruit motor units (Amann et  
151 al. 2011; Hureau et al. 2019).

152

153 A challenge in studying the fatigue-pain relationship (Mauger 2013; Pollak et al. 2014) is that  
154 most experimental pain-induction methods are notably different in their processing and  
155 response compared with the transmission and experience of EIP (i.e. differences in the  
156 neurological processes that result in the perception of pain, from transduction to perception  
157 (Olesen et al. 2012)). For example, ischemic, electrical and thermal pain induction are



158 experimental pain models that are non-specific to the muscle, and can also induce the  
159 perception of cutaneous pain (Staahl and Drewes 2004; Olesen et al. 2012). The additional  
160 stimulation of these superficial tissues can produce a subjective pain quality described as  
161 “sharp” or “stabbing” as opposed to the “aching” or “cramping” nature of muscle pain  
162 (Mense 1993). As such their use may be inappropriate in the investigation of EIP.

163  
164 Consequently, an experimental model that induces muscle pain that feels like naturally  
165 occurring EIP and allows its contribution to fatigue to be investigated by decoupling EIP  
166 from exercise intensity is desirable. The intramuscular injection of hypertonic saline is a well-  
167 established and safe experimental method that, under resting conditions, induces standardised  
168 and reproducible acute pain often described as ‘aching’ and ‘cramping’ (Graven-Nielsen et  
169 al. 1997a, b, c). When injected, this solution activates predominantly group IV afferents with  
170 some contribution from myelinated group III nerve fibres (Laursen et al. 1999), which is  
171 similar to the nociceptive pathway of EIP (O’Connor and Cook 1999).

172  
173 However, while hypertonic saline is established for inducing muscle pain, there has been  
174 limited comparison with the experience of EIP and minimal application to explore the  
175 fatigue-pain relationship. Indeed, in this field hypertonic saline is most widely used to  
176 investigate putative pain-induced changes to motor control (Hodges and Tucker 2011),  
177 maximal voluntary contraction (Graven-Nielsen et al. 2002), and high intensity, short  
178 duration exercise performance (Graven-Nielsen et al. 1997d) rather than its impact on  
179 exercise-induced fatigue. In addition, the exercise intensities, durations, and muscle groups  
180 used in these studies have limited relevance to exercise conditions where the impact of EIP  
181 on fatigue is most prominent (i.e. prolonged duration (> 2 min), exhaustive exercise in large,

182 primary muscle groups involved in locomotive exercise) (Cook et al. 1997; Abbiss and  
183 Laursen 2008).

184

185 Therefore, the aims of this study were to: (i) compare the qualitative experience (based on the  
186 total and subclass scores from the McGill Pain Questionnaire) of naturally occurring EIP to  
187 the pain elicited from an intramuscular injection of hypertonic saline into a locomotor  
188 muscle; and (ii) identify the effects of the muscle pain elicited by this method on the  
189 performance time of an endurance exercise task. We tested the hypothesis that the addition of  
190 an intramuscular injection of 5.8% hypertonic saline into the vastus lateralis (VL) to low  
191 intensity exercise: (i) produces a similar quality of pain (as defined by the McGill Pain  
192 Questionnaire) compared to naturally occurring EIP caused by a higher exercise intensity;  
193 and (ii) results in a shorter time to task failure compared to placebo and control conditions.

194

## 195 **METHODS**

### 196 *Ethical approval*

197 The School of Sport and Exercises (University of Kent) Research Ethics Advisory Group  
198 (Prop 84\_2016\_17) approved all procedures and protocols in accordance with the Declaration  
199 of Helsinki. Written informed consent was gained from the participants prior to participation.

200

### 201 *Participants*

202 Eighteen healthy and recreationally active participants (11 male, 7 female; mean  $\pm$  SD: age,  
203  $24.5 \pm 4.0$  years; height  $1.76 \pm 0.1$  m; body mass  $73.9 \pm 13.4$  kg; physical activity  $5.5 \pm 2.3$   
204  $\text{h} \cdot \text{w}^{-1}$ ) volunteered to participate in the present study. The sample size was estimated based on  
205 the effect size reported in a similar exercise and pain study (Deschamps et al. 2014) to satisfy  
206 statistical power at 80%. All participants attended each visit in a similar psychological state

207 as assessed by the Positive and Negative Affect Schedule (PANAS) (Watson et al. 1988),  
208 which was completed at the start of each visit.

209

210 Participants with existing knee pain, cardiorespiratory disease, neurological disorders, blood  
211 borne viruses (e.g. hepatitis B/C and HIV), sore deep tissues, phobia to needles and any  
212 allergy were excluded from the study. Participants consuming supplements or medications  
213 that alter pain perception during the course of the study were also excluded. Before each visit,  
214 participants were instructed to refrain from vigorous exercise (24 h) and abstain from the  
215 consumption of alcohol (48 h), analgesics (6 h) and caffeine (8 h).

216

### 217 ***Experimental procedures***

218 Participants attended the laboratory on five occasions, with each visit separated by 2-7 days.  
219 In the initial visit, anthropometric measures were recorded, and participants were familiarized  
220 with all measures relating to the experimental protocol, including a practice of knee extensor  
221 maximal voluntary contractions (MVCs). Five minutes after MVCs, participants performed  
222 an isometric time to task failure (TTF) at 20% maximal voluntary torque (MVT). In visit 2,  
223 participants received a single injection of hypertonic saline (Rest HYP), whilst seated at rest  
224 (*see intramuscular injection procedure*). Upon the completion of the injection, participants  
225 were asked to continuously rate muscle pain intensity, with the visit concluding once the  
226 participant had returned to the state of 'no pain'. In a further three visits (visits 3-5),  
227 participants performed a TTF at 10% MVT in three conditions in the presence of: no  
228 injection (10% MVT, Control), isotonic saline (10% MVT + ISO, Placebo) and hypertonic  
229 saline (10% MVT + HYP). In the 10% MVT + ISO and 10% MVT + HYP visits, an  
230 intramuscular injection was administered prior to the TTF, with the task commencing within

231 3 s of needle removal. Conditions were performed in a single-blind, randomised and counter-  
232 balanced order.

233

#### 234 *Time to task failure (TTF) protocol*

235 All visits were performed seated on an isokinetic dynamometer (Cybex HUMAC Norm  
236 isokinetic dynamometer; CSMi, Soughton, MA, USA), set up for the right leg with knee  
237 angle at 75° flexion (0° = full extension of the knee), and a hip angle at 90°. At the start of  
238 each visit, participants completed a 5 min self-paced, submaximal warm-up on a cycle  
239 ergometer (Wattbike Ltd, Nottingham, UK) followed by 3×3s MVCs separated by 90 s rest.  
240 The highest torque produced across the three MVCs was defined as the MVT. The TTF  
241 commenced 5 min after the MVCs, with the participants directed to maintain a submaximal  
242 isometric contraction of the knee extensors. The participants received visual feedback of the  
243 target torque on a computer screen but were unaware of the overall time elapsed. The task  
244 was limited to a maximum of 20 min, or was terminated when the torque fell below the target  
245 for more than 3 s. Within 3 s of task cessation participants performed a final MVC.

246

#### 247 *Intramuscular injection procedure*

248 A single bolus of 1.0 mL 5.8% hypertonic saline was injected in the VL (middle third of the  
249 lateral aspect of the thigh) of the right leg to induce acute muscle pain. Injection of a single  
250 bolus of 1.0 mL 0.9% isotonic saline was implemented as a placebo. The injection was  
251 performed manually in a 20 s window (10 s infusion period) using a 3 mL Luer-Lok syringe  
252 connected to a 25 G × 38 mm SurGuard2 disposable stainless needle (Terumo, Japan).

253

#### 254 *Perceptual measurements*

255 At the start of each visit, participants were asked to rate (on a visual analogue scale) how  
256 much pain they expected to experience (anchored to the non-injury pain experienced during  
257 exercise) (0 = “no pain” to 10 = “worst possible pain”) and their confidence to cope with the  
258 expected level of pain (0 = “not confident at all” to 10 = “completely confident”). This  
259 provides a measure of pain-specific self-efficacy which is believed to a predictor of pain  
260 tolerance and endurance (Motl et al. 2007; Schmitz et al. 2013). Two characteristics of pain  
261 were evaluated: intensity and quality. During all visits, pain intensity was continuously  
262 scored on a moment-to-moment basis using an electronic visual analogue scale (VAS)  
263 ranging from 0 (“no pain”) to 10 (“extremely intense pain”) (Cook et al. 1997) and anchored  
264 to previous experiences of naturally occurring EIP (Astokorki and Mauger 2017). The device  
265 automatically sampled and recorded the reported pain intensity every 5 s, which allowed for  
266 values such as VAS onset (the time-point at which the stimulus is first perceived to be greater  
267 than “no pain”) peak pain intensity (VAS peak), time to maximal intensity (from the  
268 commencement of sampling), mean pain intensity (the mean VAS from the commencement  
269 of sampling until task failure), duration of pain (from VAS onset until the state of “no pain”),  
270 and VAS area (area under VAS curve) to be calculated.

271

272 The quality of pain was established by the long-form McGill Pain Questionnaire (MPQ)  
273 (Melzack 1975) which contains a total of 20 categories of adjectives describing four major  
274 subclasses of pain experience (sensory, affective, evaluative and miscellaneous). Each  
275 category contains between two to six similar adjectives arranged in ascending order of  
276 implied pain intensity and are assigned rank value based on this order (e.g. the descriptor  
277 associated with the least pain within the category is assigned a value of 1). Participants were  
278 permitted to select a maximum of one word per category (should any of the descriptors  
279 apply). The descriptors chosen by the participants were subsequently summed to calculate

280 scores for each subclass (Subclass Rating Index) and the total score of all subclasses (Total  
281 Pain Rating Index), with the overall quality of pain expressed by descriptors chosen by more  
282 than one-third of participants. The MPQ was completed after the post-TTF MVC in each  
283 visit, and the return to “no pain” in the Rest HYP visit.

284

285 During all of the TTF trials at 10% MVT (visits 3-5), participants also reported Rating of  
286 perceived exertion (RPE), defined as the effort to drive the limb (Pageaux et al. 2015), using  
287 the 15-point Borg (6-20) scale (Borg 1998) every 30 s. Rating of Fatigue, the perceived  
288 inability of the muscle to produce torque, was recorded every 30 s for the first min, and every  
289 60 s thereafter using the 11-point Rating of Fatigue (ROF) scale (Micklewright et al. 2017).

290

### 291 *Physiological Measurements*

292 During the TTFs at 10% MVT (visits 3-5) heart rate (HR) was recorded every 30 s using a  
293 Polar FT1 HR monitor paired with a coded T34 transmitter (Polar, Polar Electro, Kempele,  
294 Finland), and muscle electrical activity was continuously recorded using surface  
295 electromyography (sEMG). sEMG was acquired with square surface electrodes (Ag/AgCl, 32  
296 × 32 mm; Nessler Medizintechnik, Innsbruck, Austria) mounted in a bipolar set-up on skin  
297 which was shaven and cleansed with an alcohol swab. Electrodes were placed over the  
298 muscle belly of the VL, rectus femoris (RF) and vastus medialis (VM) in the direction of the  
299 muscle fibres, with a reference electrode placed on the patella. The electrical signal was  
300 sampled at 2000 Hz (Biopac MP150, Biopac Systems Inc., California, USA) and acquired in  
301 Spike2 software (Version 7; Cambridge Electronic Design).

302

303 The sEMG data was analysed using custom code written in MATLAB R2018a (The  
304 MathWorks, Massachusetts, USA). To create a linear envelope representation of the data, the

305 raw sEMG signals were rectified by taking the absolute values, and two-pass zero-lag filtered  
306 using a fourth-order low-pass Butterworth filter with a cut-off frequency of 5 Hz. To analyse  
307 changes over time, the signals were divided into 10 s epochs. The mean sEMG amplitude for  
308 the VL, RF and VM over each 10 s epoch was extracted and normalised to the maximum  
309 sEMG amplitude of the prior MVCs (% MVC).

310

### 311 *Statistical analysis*

312 All data are presented in the form of mean  $\pm$  standard deviation (SD). Prior to statistical  
313 analysis, all data were checked for the assumptions associated with a paired samples t-test, a  
314 one-way ANOVA and a repeated measures ANOVA as appropriate. Data that did not satisfy  
315 the Shapiro-Wilk test of normality ( $P < 0.05$ ) were logarithmically transformed. The  
316 Bonferroni post-hoc correction was applied where appropriate. Cohen's  $d$  and partial eta  
317 square ( $\eta_p^2$ ) values are reported as measures of effect size (Cohen, 1988).

318

319 Due to between subject variability in TTF, an 'individual iso-time' approach as outlined by  
320 Nicolò and colleagues (Nicolò et al. 2019) was applied to compare perceptual (pain intensity,  
321 RPE, ROF) and physiological (HR, sEMG) variables. The 'shortest' TTF for each participant  
322 was used to identify four (RPE, ROF, HR) and ten (pain intensity and sEMG) time-points in  
323 which the three conditions were segmented. This approach maintains a majority of the time-  
324 series data (i.e. allows for the inclusion of all repeated recordings such as pain, RPE and ROF  
325 to be included) and provides a consistent number of data points to allow comparison between  
326 participants for all stated variables across the varying TTF times.

327

328 A two-way ANOVA with Treatment factor with 3 fixed levels (10% MVT, 10% MVT + ISO,  
329 10% MVT + HYP) and a repeated measures Time factor with 10 time-points was used to test

330 the effect of condition and time on pain intensity and sEMG during the TTF. Two-way  
331 ANOVAs with a Treatment factor with 3 fixed levels (10% MVT, 10% MVT + ISO,  
332 Experimental) and a repeated measures Time factor with 4 time points were used for  
333 measures of RPE, ROF and HR recorded during the TTF. When an interaction effect was  
334 observed, post-hoc paired sample t-tests were implemented to evaluate differences between  
335 conditions. Statistical significance was accepted at an alpha level of  $P < 0.05$  except where a  
336 Bonferroni correction was applied (adjusted,  $P < 0.0042$ ). All statistics were performed using  
337 SPSS Statistics v24.0 (SPSS, IBM, New York, USA).

338

## 339 **RESULTS**

340 As the TTF task was limited to a maximum of 20 min, participants that met this cut-off in any  
341 condition did not reach task failure or ‘exhaustion’, which does not provide a true indication  
342 of endurance performance. To account for this, these participants ( $n = 6$ ) were subsequently  
343 removed from the data set, and analysis was performed on the subset of participants ( $n = 12$ ).

344

### 345 *Comparison of pain intensity and quality*

346 Mean TTF at 20% MVT was  $193 \pm 50$  s. As shown in Table 1, paired samples t-test revealed  
347 a significant difference in VAS scores between pain intensity during 20% MVT TTF and  
348 experimental muscle pain from Rest HYP ( $P < 0.05$ ). The 20% MVT task induced a  
349 significantly greater mean VAS, equivalent to between “somewhat strong” and “strong” pain  
350 intensity ( $t_{11} = 5.3$ ,  $P < 0.001$ ,  $CI_{95} 1.1, 2.6$ ,  $d = 1.8$ ), which peaked after a longer period of  
351 time ( $t_{11} = 5.6$ ,  $P < 0.001$ ,  $CI_{95} 64, 147$ ,  $d = 1.7$ ) and lasted for a shorter duration ( $t_{11} = -3.9$ ,  $P$   
352  $= 0.002$ ,  $CI_{95} -175, -49$ ,  $d = 1.7$ ) than the experimental muscle pain experienced in Rest HYP.

353



354 Differences in VAS scores were also reported between 20% TTF and the TTFs at 10% MVT  
355 ( $P < 0.05$ ). The VAS onset was significantly slower in 10% MVT ( $t_{11} = -5.0$ ,  $P < 0.001$ ,  $CI_{.95}$   
356  $-44, -17$ ,  $d = 1.0$ ) and 10% MVT + ISO ( $t_{11} = -2.3$ ,  $P = 0.043$ ,  $CI_{.95}$   $-33, -1$ ,  $d = 0.7$ ), with a  
357 quicker onset in 10% MVT + HYP ( $t_{11} = 2.2$ ,  $P = 0.0047$ ,  $CI_{.95}$   $0.2, 29$ ,  $d = 0.9$ ). A greater  
358 VAS mean, equivalent to between “strong” and “very strong” pain was observed in the 10%  
359 MVT + HYP condition compared to 20% MVT ( $t_{11} = -2.8$ ,  $P = 0.017$ ,  $CI_{.95}$   $-2.6, -0.3$ ,  $d =$   
360  $1.1$ ) and 10% MVT ( $t_{11} = -2.3$ ,  $P = 0.044$ ,  $CI_{.95}$   $-1.97, -0.03$ ,  $d = 0.6$ ).

361

362 The VAS in all three conditions performed at 10% MVT peaked after a longer period of time  
363 (10% MVT;  $t_{11} = -6.5$ ,  $P < 0.001$ ,  $CI_{.95}$   $-344, -170$ ,  $d = 2.0$ , 10% MVT + ISO;  $t_{11} = -4.9$ ,  $P <$   
364  $0.001$ ,  $CI_{.95}$   $-484, -185$ ,  $d = 1.7$ , 10% MVT + HYP;  $t_{11} = -3.5$ ,  $P = 0.005$ ,  $CI_{.95}$   $-321, -74$ ,  $d =$   
365  $1.2$ ) and lasted longer in duration (10% MVT;  $t_{11} = -6.3$ ,  $P < 0.001$ ,  $CI_{.95}$   $-394, -189$ ,  $d = 2.2$ ,  
366 10% MVT + ISO;  $t_{11} = -5.6$ ,  $P < 0.001$ ,  $CI_{.95}$   $-538, -234$ ,  $d = 2.0$ , 10% MVT + HYP;  $t_{11} = -$   
367  $4.2$ ,  $P = 0.001$ ,  $CI_{.95}$   $-411, -130$ ,  $d = 1.6$ ) than the 20% MVT condition. This contributed to a  
368 greater VAS area (10% MVT;  $t_{11} = -5.4$ ,  $P < 0.001$ ,  $CI_{.95}$   $-2551, -1077$ ,  $d = 1.9$ , 10% MVT +  
369 ISO;  $t_{11} = -5.9$ ,  $P < 0.001$ ,  $CI_{.95}$   $-3233, -1466$ ,  $d = 2.2$ , 10% MVT + HYP;  $t_{11} = -4.4$ ,  $P =$   
370  $0.001$ ,  $CI_{.95}$   $-2754, -929$ ,  $d = 1.7$ ) in the 10% MVT conditions compared to 20% MVT.

371

372 Overall, as shown in Table 2, the dimensional quality of pain experienced during 20% MVT  
373 was similar to Rest HYP for the sensory ( $P = 0.123$ ) and miscellaneous ( $P = 0.189$ )  
374 dimensions, but not for the affective ( $P = 0.008$ ) and evaluative ( $P = 0.007$ ) subclasses. The  
375 20% MVT task produced a greater mean Total Pain Index of  $30 \pm 11$  ( $t_{11} = 2.9$ ,  $P = 0.016$ ,  
376  $CI_{.95}$   $2, 18$ ,  $d = 0.7$ ) than Rest HYP ( $20 \pm 9$ ), and, as shown in Table 2, and was defined by  
377 descriptives representing all dimensions in the MPQ. However, the 10% MVT + HYP  
378 condition, with a mean total pain index of  $29 \pm 14$ , produced a similar overall subjective

379 quality of pain to 20% MVT ( $t_{11} = 0.3$ ,  $P = 0.743$ ,  $CI_{.95} -6, 8$ ,  $d = 0.1$ ). Paired samples t-test  
 380 revealed no significant difference in Subclass Rating Index between 10% MVT + HYP and  
 381 10% MVT (Sensory;  $P = 0.704$ , Affective:  $P = 0.429$ , Evaluative;  $P = 0.878$ ; Miscellaneous,  
 382  $P = 0.410$ ) as well as 10% MVT + HYP and 20% MVT (Sensory;  $P = 0.941$ , Affective:  $P =$   
 383  $0.394$ , Evaluative;  $P = 0.504$ ; Miscellaneous,  $P = 0.810$ ) for all classifications (Table 2).

384

385

386 **Table 1.** Summary VAS scores from 20% MVT, Rest HYP, 10% MVT, 10% MVT + ISO,  
 387 10% MVT + HYP TTF.

	20% MVT	Rest HYP	10% MVT	10% MVT + ISO	10% MVT + HYP
VAS onset (s)	25 ± 22	7 ± 16	55 ± 36**	42 ± 29*	10 ± 9*
VAS mean	4.8 ± 1.0	3.0 ± 1.0**	5.3 ± 1.4	5.5 ± 1.2	6.3 ± 1.7*†
VAS peak	9.7 ± 0.7	5.8 ± 2.1**	9.5 ± 0.8	9.0 ± 1.5	9.2 ± 1.6
VAS time to peak (s)	181 ± 51	75 ± 31**	438 ± 171**	516 ± 282**	379 ± 229*
VAS duration (s)	168 ± 42	281 ± 84*	459 ± 185**	555 ± 270**	438 ± 241*
VAS area	899 ± 315	869 ± 386	2713 ± 1282**	3248 ± 1493**	2740 ± 1521*

388

389 Values are means ± SD. \*Significantly different vs 20% MVT ( $P < 0.05$ ). \*\*Significantly  
 390 different vs 20% MVT ( $P < 0.001$ ). †Significantly different vs 10% MVT ( $P < 0.05$ )

391

392

393

394 *Time to task failure (TTF)*

395 An ANOVA revealed a significant difference between conditions ( $F_{2,22} = 6.7$ ,  $P = 0.005$ ,  $\eta_p^2$   
 396  $= 0.378$ ) with 10% MVT + HYP causing a significantly ( $t_{11} = 3.4$ ,  $P = 0.006$ ,  $CI_{.95} 55, 257$ ,  $d$   
 397  $= 0.6$ ) shorter TTF ( $448 \pm 240$  s) compared to both 10% MVT + ISO ( $605 \pm 285$  s), and 10%  
 398 MVT ( $514 \pm 197$  s) ( $t_{11} = 2.3$ ,  $P = 0.040$ ,  $CI_{.95} 4, 127$ ,  $d = 0.3$ ) (Fig. 1a.). No significant

399 differences were observed between 10% MVT and 10% MVT + ISO ( $t_{11} = -1.8$ ,  $P = 0.104$ ,  
400  $CI_{.95} -204$ ,  $22 d = 0.4$ ).


401

402 Paired samples t-tests showed that post-TTF MVT significantly decreased in 10% MVT (pre  
403 =  $304 \pm 56$  N.m, post =  $191 \pm 62$  N.m), 10% MVT + ISO (pre =  $300 \pm 62$  N.m, post =  $197 \pm$   
404  $64$  N.m) and 10% MVT + HYP (pre =  $308 \pm 65$  N.m, post =  $187 \pm 66$  N.m) in comparison to  
405 pre-TTF MVT ( $P < 0.001$ ). No significant difference was observed between conditions for  
406 absolute decrement in MVT ( $F_{2,22} = 1.0$ ,  $P = 0.379$ ,  $\eta_p^2 = 0.204$ ). An ANOVA also  
407 demonstrated no significant difference between conditions for positive affect ( $F_{2,22} = 1.8$ ,  $P =$   
408  $0.189$ ,  $\eta_p^2 = 0.141$ ), and negative affect ( $F_{2,22} = 1.4$ ,  $P = 0.263$ ,  $\eta_p^2 = 0.114$ ) recorded prior to  
409 the TTF.

410

411

412



413

414 **Fig. 1** Performance and perceptual differences between conditions. TTF differences

415 between conditions (a), and pain intensity (b) and RPE (c) and ROF (d) over iso-time between conditions during

416 the TTF. \*Significant difference between conditions ( $P < 0.05$ ). \*\*Significant difference between 10% MVT +

417 HYP and 10% MVT ( $P \leq 0.001$ ). #Significant difference between 10% MVT + HYP and 10% MVT + ISO ( $P <$

418 0.001). §Significant main effect of iso-time.

419

#### 420 *Pain intensity*

421 An ANOVA revealed a significant difference in pain expectations between conditions ( $F_{2,22} =$

422 9.6,  $P = 0.001$ ,  $\eta_p^2 = 0.467$ ), but not in confidence to cope with the expected pain ( $F_{2,22} = 2.3$ ,

423  $P = 0.125$ ,  $\eta_p^2 = 0.172$ ). Subsequent pairwise comparisons found greater expectations of pain

424 in 10% MVT + ISO ( $7.2 \pm 1.9$ ) ( $t_{11} = -3.8$ ,  $P = 0.003$ ,  $CI_{95} -2, -1$ ,  $d = 0.7$ ) and 10% MVT +

425 HYP ( $7.5 \pm 1.3$ ) ( $t_{11} = -4.5$ ,  $P = 0.001$ ,  $CI_{95} -2, -1$ ,  $d = 1.0$ ) compared to 10% MVT ( $6.0 \pm 1.6$ )

426 with no significant difference between 10% MVT + ISO and 10% MVT + HYP ( $t_{11} = -0.7$ ,  $P$

427  $= 0.518$ ,  $CI_{95} -1, 1$ ,  $d = 0.2$ ).

428

429 The  $3 \times 10$  (condition  $\times$  iso-time) repeated measures ANOVA highlighted a significant effect  
430 of condition ( $F_{2,22} = 6.5, P = 0.006, \eta_p^2 = 0.372$ ) and iso-time ( $F_{2,8,31.2} = 82.2, P < 0.001, \eta_p^2$   
431  $= 0.882$ ) for perceived pain during the TTF (Fig. 1b.). A significant interaction effect for pain  
432 over iso-time between conditions during the TTF was observed ( $F_{3,9,42.4} = 3.4, P = 0.018, \eta_p^2$   
433  $= 0.236$ ). Follow up targeted paired-sample t-tests with a Bonferroni correction revealed a  
434 significantly greater VAS pain intensity at 10% iso-time ( $43 \pm 21$  s) in 10% MVT + HYP  
435 compared to both 10% MVT ( $t_{11} = -6.4, P < 0.001, CI_{.95} -43.7, -21.3, d = 1.9$ ) and 10% MVT  
436 + ISO ( $t_{11} = -5.8, P < 0.001, CI_{.95} -44.2, -19.9, d = 1.9$ ) and at 20% iso-time ( $86 \pm 42$  s) in  
437 contrast with 10% MVT ( $t_{11} = -4.3, P = 0.001, CI_{.95} -42.1, -13.4, d = 1.3$ ) and 10% MVT +  
438 ISO ( $t_{11} = -6.3, P < 0.001, CI_{.95} -38.9, -18.6, d = 1.5$ ).

439

#### 440 *Perceptual measurements*

441 The  $3 \times 4$  (condition  $\times$  iso-time) repeated measures ANOVA revealed no significant main  
442 effect of condition for ROF or RPE ( $P > 0.05$ ). Both ROF and RPE had a significant effect of  
443 iso-time (ROF;  $F_{1,4,15.9} = 104.1, P < 0.001, \eta_p^2 = 0.904$ , RPE;  $F_{1,5,16.3} = 87.8, P < 0.001, \eta_p^2 =$   
444  $0.889$ ), and an interaction effect (ROF;  $F_{2,1,23.4} = 6.9, P = 0.004, \eta_p^2 = 0.387$ , RPE;  $F_{2,8,31.1} =$   
445  $4.6, P = 0.010, \eta_p^2 = 0.296$ ) (Fig. 1c. and Fig. 1d.). Follow-up paired samples t-tests with a  
446 Bonferroni correction ( $P > 0.004$ ) revealed no significant differences at any iso-time point  
447 between conditions for both ROF and RPE.


448

#### 449 *Surface electromyography (sEMG)*

450 Due to a loss in sEMG signal, two participants were removed from the dataset and analysis  
451 was performed on the remaining participants ( $n = 10$ ). A  $3 \times 10$  (condition  $\times$  iso-time)  
452 repeated measures ANOVA demonstrated no significant main effect of condition in either the

453 VL ( $F_{2,18} = 1.3$ ,  $P = 0.288$ ,  $\eta_p^2 = 0.129$ ), VM ( $F_{2,18} = 1.9$ ,  $P = 0.174$ ,  $\eta_p^2 = 0.177$ ) or RF  
454 ( $F_{2,18} = 0.5$ ,  $P = 0.613$ ,  $\eta_p^2 = 0.053$ ). A significant effect of iso-time in the activity of the VL  
455 ( $F_{1.5,13.2} = 19.3$ ,  $P < 0.001$ ,  $\eta_p^2 = 0.682$ ), VM ( $F_{1.8,16.4} = 14.2$ ,  $P < 0.001$ ,  $\eta_p^2 = 0.612$ ), and RF  
456 ( $F_{2.0,18.2} = 6.7$ ,  $P = 0.007$ ,  $\eta_p^2 = 0.426$ ) was reported (Fig. 2). There was no interaction effect  
457 observed in the RF ( $F_{18,162} = 0.4$ ,  $P = 0.994$ ,  $\eta_p^2 = 0.037$ ). A significant interaction effect was  
458 reported for VL ( $F_{18,162} = 3.5$ ,  $P < 0.001$ ,  $\eta_p^2 = 0.278$ ) and VM ( $F_{18,162} = 2.2$ ,  $P = 0.006$ ,  $\eta_p^2$   
459  $= 0.195$ ) activity over iso-time between conditions, however subsequent follow-up targeted  
460 paired sample t-tests with a Bonferroni correction demonstrated no significant differences  
461 (Fig. 3a-3c).

462




463

464 **Fig. 2** Torque and sEMG data during the TTF of the 10% MVT (a), 10% MVT + ISO (b) and 10% MVT +

465 HYP (c) conditions for a representative participant. The TTF was significantly shortened in the 10% MVT +

466 HYP condition (note the relative time scale).

467



468

469 **Fig. 3** Physiological differences between conditions. EMG of the VL (a), VM (b) and RF (c) over iso-time  
 470 between conditions during the TTF. HR differences between conditions over iso-time during the TTF (d).  
 471 §Significant main effect of iso-time ( $P < 0.05$ ).

472

473

474 *Heart rate (HR)*

475 The  $3 \times 4$  (condition  $\times$  iso-time) repeated measures ANOVA revealed no significant main  
 476 effect of condition ( $F_{1.3,14.1} = 0.8$ ,  $P = 0.404$ ,  $\eta_p^2 = 0.071$ ). There was a significant effect of  
 477 iso-time ( $F_{1.1,12.3} = 39.6$ ,  $P < 0.001$ ,  $\eta_p^2 = 0.783$ ), and an interaction effect for HR and iso-time  
 478 between conditions during the TTF ( $F_{1.7,18.9} = 6.0$ ,  $P = 0.012$ ,  $\eta_p^2 = 0.352$ ). Subsequent paired  
 479 samples t-test with a Bonferroni correction revealed no significant differences between  
 480 conditions (Fig. 3d).

481

482



483 **Table 2.** Frequently selected words from the MPQ subclasses

Subclass	20% MVT	REST HYP	10% MVT	10% MVT + ISO	10% MVT + HYP	
Sensory	Throbbing (33%)	Throbbing (50%)	Lacerating (33%)	Throbbing (50%)	Throbbing (58%)	
	Sharp (58%)	Shooting (42%)	Cramping (58%)	Cramping (41%)	Drilling (33%)	
	Cramping (33%)	Sharp (33%)	Pulling (33%)	Burning (50%)	Cramping (67%)	
	Pulling (33%)	Cramping (67%)	Searing (33%)	Aching (67%)	Burning (42%)	
	Hot (33%)	Aching (67%)	Aching (50%)		Aching (50%)	
	Burning (33%)	Tender (33%)			Heavy (33%)	
	Hurting (33%)					
	Aching (58%)					
	SRI	18 ± 6	15 ± 6	18 ± 9	15 ± 6	18 ± 9
	Affective	Exhausting (50%)		Exhausting (75%)	Tiring (33%) Gruelling (33%)	Tiring (42%) Exhausting (42%) Gruelling (33%)
SRI		3 ± 3	1 ± 1*	3 ± 2	2 ± 2	3 ± 2
Evaluative	Intense (50%)	Intense (33%)	Intense (58%)	Intense (67%)	Intense (67%)	
	SRI	4 ± 2	2 ± 2*	3 ± 2	3 ± 1	3 ± 1
Miscellaneous	Radiating (33%) Tight (33%)	Radiating (33%)				
	SRI	5 ± 4	3 ± 3	4 ± 3	5 ± 4	5 ± 4
	PRI(T)	30 ± 11	20 ± 9*	28 ± 12	26 ± 11	29 ± 14

484 The frequently selected words from the MPQ are shown with the percentage of participants  
 485 that selected these words. Data on Subclass Rating Index (SRI) and Pain Rating Index (Total)  
 486 presented as Mean ± SD. \*Significantly different vs 20% MVT (P < 0.05). \*\*Significantly  
 487 different vs 20% MVT (P < 0.001). †Significantly different vs 10% MVT (P < 0.05)

488

489

## 490 **DISCUSSION**

491 This study confirms that the pain experienced during knee extensor exercise at 10% MVT can  
492 be made to feel like that of a higher exercise intensity, through the intramuscular injection of  
493 hypertonic saline into the VL. Using this intervention, exercise-induced fatigue occurred  
494 more rapidly, with participants reaching task failure earlier when exercising with a greater  
495 pain intensity (Fig. 1b). This study therefore provides indicative evidence to support the  
496 notion that pain is a significant factor affecting endurance exercise performance.

497

### 498 *Hypertonic saline combined with light exercise feels like EIP*

499 The novel question the present study strived to determine was whether the addition of  
500 hypertonic saline to light intensity exercise at 10% MVT produces an elevated pain intensity  
501 which also feels similar to the naturally occurring EIP during a higher exercise intensity (20%  
502 MVT). Thus, the first key finding from this study is that when combined with light exercise  
503 (10% MVT), the hypertonic saline induced a descriptive quality of pain similar to the EIP  
504 from both the 10% and 20% MVT exercise tasks (but with a higher intensity). This is in  
505 contrast to the administration of hypertonic saline at rest, where our findings were consistent  
506 with the established literature - a moderate to somewhat strong pain, described as cramping,  
507 aching, throbbing and intense (Graven-Nielsen et al. 1997a, b, c). Furthermore, in these  
508 resting conditions, whilst the sensory and miscellaneous quality of experimental pain was  
509 similar to the naturally occurring EIP experienced during the 20% MVT task, there were  
510 differences in pain intensity and quality. In particular, the 20% MVT task produced a higher  
511 pain intensity that was also described in the affective (e.g. 'exhausting') dimension. This  
512 suggests that for hypertonic saline to induce a pain that feels like EIP, it needs to be *combined*  
513 with at least light intensity exercise. When this was done, participants experienced an

514 elevated overall intensity of pain (compared to both 10% and 20% MVT) but were unable to  
515 distinguish between the experimental muscle pain produced by the hypertonic saline and the  
516 EIP from the muscular contraction. The findings of this study therefore provide support for  
517 this hypertonic saline model for uncoupling the exercise intensity and EIP relationship (Cook  
518 et al. 1997) – i.e. causing a light exercise intensity to *feel* like a harder exercise intensity.

519

#### 520 *Effect of pain on isometric TTF*

521 The present study demonstrates that greater levels of pain in a fresh, undamaged, large  
522 locomotor muscle group significantly shortens TTF during an isometric endurance task.  
523 Indeed, TTF was significantly shorter in the 10% MVT + HYP condition than both the 10%  
524 MVT and 10% MVT + ISO conditions, with an impaired performance of 12 to 26%. As all  
525 conditions were performed at the same intensity (10% MVT) and with participants in a  
526 similar psychological state, these differences in TTF can be attributed solely to increasing the  
527 experience of pain in the 10% MVT + HYP condition, as clearly shown in Figure 1b.

528

529 Previous research that has used hypertonic saline to induce muscle pain have predominantly  
530 applied it in smaller muscles or muscle groups (e.g. biceps brachii, tibialis anterior and  
531 gastrocnemius (Graven-Nielsen et al. 1997d; Ciubotariu et al. 2004; Khan et al. 2011)) and  
532 have not focused on producing a pain experience that feels like EIP. The VL is a large muscle  
533 with a key role in the generation of force during basic locomotor tasks (e.g. walking, stair  
534 climbing) and contributes to propulsive energy during cycling (Raasch et al. 1997), as well as  
535 the stance and swing phase in running (Sasaki and Neptune 2006). Understanding the effects  
536 of an increased overall pain experience in this muscle (and surrounding knee extensor group)  
537 at a contraction intensity utilised during cycling exercise (Löllgen et al. 1980) therefore  
538 provides information that closely translates to exercise performance and a clinical context.

539 Care should however be taken when extrapolating findings to whole-body exercise or  
540 dynamic contraction.

541

542 During the impaired TTF performance in the 10% MVT + HYP condition, pain intensity was  
543 significantly elevated in the first 20% of the task, with a continued linear increase until task  
544 failure. Indeed, the intensity of pain reported in the 10% MVT + HYP condition was elevated  
545 by approximately 3.3 at 10% iso-time and 2.8 at 20% iso-time on the VAS scale. The  
546 hypertonic saline in the 10% MVT + HYP condition would have increased the activation of  
547 the group III and IV nociceptive afferents *in addition* to the rapidly increasing noxious  
548 environment arising from the metabolites produced as a result of the exercise task (O'Connor  
549 and Cook 1999), which might explain the shorter TTF in the 10% MVT + HYP condition.

550

551 This explanation is in accordance with the “Sensory Tolerance Limit”, where in open-loop  
552 exercise tasks (i.e. TTF) the increased inhibitory feedback from Group III and IV afferents  
553 contributes to an individual and task-specific threshold, which when reached the exercise is  
554 voluntarily terminated (Amann and Dempsey 2008; Amann 2011). With similar values for  
555 RPE and ROF between conditions it is likely the elevated pain intensity during the TTF at  
556 10% MVT + HYP resulted in this sensory tolerance limit being reached sooner, causing a  
557 faster occurrence of task failure compared to the 10% MVT and 10% MVT + ISO conditions  
558 (Aboodarda et al. 2020).

559

560 In addition, the increased nociceptive activity (a specific type of afferent feedback) may have  
561 limited central motor drive and voluntary activation of the knee extensors (Amann et al.  
562 2009, 2011; Aboodarda et al. 2020), a notion which is supported by evidence showing a  
563 relationship between group III and IV muscle afferents and neuromuscular fatigue (Amann et

564 al. 2015; Sidhu et al. 2018), In support of this, Henriksen and colleagues (Henriksen et al.  
565 2011) reported a reduced capacity of the knee extensors to produce a MVT in the presence of  
566 pain. Furthermore, findings from Graven-Nielsen and colleagues (Graven-Nielsen et al.  
567 2002) demonstrated that experimental muscle pain (from the hypertonic saline model)  
568 reduces MVT despite an unaffected twitch torque, implying that performance decrements  
569 were due to mechanisms residing in the central nervous system rather than the peripheral  
570 musculature (Graven-Nielsen et al. 2002).

571

572 Rather than a uniform inhibitory/facilitatory effect on agonist and antagonist muscle activity  
573 (Pain Adaptation Model, Lund et al. 1991), it is now recognised that pain does not cause  
574 uniform inhibition/excitation effects across the motor neurone pool, but instead causes a  
575 redistribution of activity within and between muscles (Hodges and Tucker 2011).

576 Accordingly, the decreased performance caused by the overall increased pain experience in  
577 the current study could also be explained by a slight change in the direction of knee extensor  
578 torque to a more lateral/medial plane (Tucker and Hodges 2010). In this context, the gross  
579 feature of the task would remain (i.e. knee extension), but the efficiency of this movement  
580 would be compromised. Motor unit recruitment order, or a recruitment of larger units at  
581 lower torques, could have also affected the task performance. In an endurance task lasting  
582 several minutes, the preferential recruitment of large high threshold motor units (which may  
583 include Type II muscle fibres) above low threshold small motor units (Type I muscle fibres)  
584 would likely have consequences for the rate at which fatigue occurs (both metabolic and  
585 neural), leading to a shorter TTF (Edwards 1981). Whilst not observed in the present study,  
586 an increase in sEMG would be indicative of an increased central drive to the muscle and/or  
587 an increased recruitment of high threshold motor units (Gerdle et al. 2000), which would be

588 in-line with Hodges and Tucker’s “moving differently in pain” theory (Hodges and Tucker  
589 2011).

590

#### 591 *Methodological considerations*

592 The methods used in this study preclude the ability to identify which, or combination of these  
593 mechanisms may have contributed to the shorter TTF. Indeed, combinations of peripheral  
594 nerve/transcranial stimulation, multiple force transducers, and fine wire electrodes would be  
595 required for this. In addition, the sensitivity of the sEMG set-up in the present study did not  
596 allow for the detection in non-uniform changes across the motor neurone pool (i.e. any  
597 alterations are unlikely to be discovered with bipolar sEMG). As such, an approach that  
598 allows for the identification of individual motor units would be more appropriate for the  
599 observation of subtle changes in activity within and between the muscles (i.e. high density  
600 EMG). Differential responses to pain between male and female participants are also  
601 acknowledged, with the present study not accounting for or attempting to control the  
602 menstrual cycle of the female participants. Indeed, hormonal changes across the different  
603 phases of the menstrual cycle may cause some difference in pain perception to experimental  
604 pain (Sherman and LeResche 2006).

605

#### 606 *Conclusion*

607 The injection of hypertonic saline into the VL during a sustained low-intensity isometric  
608 contraction provides an overall qualitative experience of pain that feels like naturally  
609 occurring EIP induced by a higher intensity exercise. When applied to submaximal exercise,  
610 this additional pain caused a shorter TTF compared with a placebo and control condition. It is  
611 plausible that the mechanisms responsible for the shorter TTF were related to increased  
612 activity of group III and IV nociceptive afferents from the injected muscle. The present study

613 therefore provides important evidence that muscle pain has a direct impact on endurance  
614 performance.

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635 **REFERENCES**

636 Abbiss CR, Laursen PB (2008) Describing and Understanding Pacing Strategies during  
637 Athletic Competition. *Sport Med* 38:239–252. [https://doi.org/10.2165/00007256-200838030-](https://doi.org/10.2165/00007256-200838030-00004)  
638 [00004](https://doi.org/10.2165/00007256-200838030-00004)  
639

640 Aboodarda SJ, Iannetta D, Emami N, et al (2020) Effects of pre-induced fatigue vs .  
641 concurrent pain on exercise tolerance, neuromuscular performance and corticospinal  
642 responses of locomotor muscles. *J Physiol* 598:285–302. <https://doi.org/10.1113/JP278943>  
643

644 Amann M (2011) Central and peripheral fatigue: Interaction during cycling exercise in  
645 humans. *Med Sci Sports Exerc* 43:2039–2045.  
646 <https://doi.org/10.1249/MSS.0b013e31821f59ab>  
647

648 Amann M, Blain GM, Proctor LT, et al (2011) Implications of group III and IV muscle  
649 afferents for high-intensity endurance exercise performance in humans. *J Physiol* 589:5299–  
650 5309. <https://doi.org/10.1113/jphysiol.2011.213769>  
651

652 Amann M, Dempsey JA (2008) Locomotor muscle fatigue modifies central motor drive in  
653 healthy humans and imposes a limitation to exercise performance. *J Physiol* 586:161–173.  
654 <https://doi.org/10.1113/jphysiol.2007.141838>  
655

656 Amann M, Proctor LT, Sebranek JJ, et al (2009) Opioid-mediated muscle afferents inhibit  
657 central motor drive and limit peripheral muscle fatigue development in humans. *J Physiol*  
658 587:271–283. <https://doi.org/10.1113/jphysiol.2008.163303>  
659



660 Amann M, Sidhu SK, Weavil JC, et al (2015) Autonomic responses to exercise: Group III/IV  
661 muscle afferents and fatigue. *Auton Neurosci* 188:19–23.  
662 <https://doi.org/10.1016/j.autneu.2014.10.018>  
663

664 Astokorki AHY, Mauger AR (2017) Transcutaneous electrical nerve stimulation reduces  
665 exercise-induced perceived pain and improves endurance exercise performance. *Eur J Appl*  
666 *Physiol* 117:483–492. <https://doi.org/10.1007/s00421-016-3532-6>  
667

668 Bigland-Ritchie B, Woods JJ (1984) Changes in muscle contractile properties and neural  
669 control during human muscular fatigue. *Muscle Nerve* 7:691–699.  
670 <https://doi.org/10.1002/mus.880070902>  
671

672 Borg GA (1998) Borg’s Perceived Exertion and Pain Scales. Champaign, IL, Human  
673 Kinetics.  
674

675 Ciubotariu A, Arendt-Nielsen L, Graven-Nielsen T (2004) The influence of muscle pain and  
676 fatigue on the activity of synergistic muscles of the leg. *Eur J Appl Physiol* 91:604–614.  
677 <https://doi.org/10.1007/s00421-003-1026-9>  
678

679 Cohen, J. (1988). *Statistical power analysis for the behavioral sciences* (2nd ed.). Hillsdale,  
680 NJ: Erlbaum.  
681

682 Cook DB, O’Connor PJ, Eubanks SA, et al (1997) Naturally occurring muscle pain during  
683 exercise: assessment and experimental evidence. *Med Sci Sports Exerc* 29:999–1012.  
684 <https://doi.org/10.1097/00005768-199708000-00004>

685

686 Deschamps T, Hug F, Hodges PW, Tucker K (2014) Influence of experimental pain on the  
687 perception of action capabilities and performance of a maximal single-leg hop. *J Pain* 15:.  
688 <https://doi.org/10.1016/j.jpain.2013.10.016>

689

690 Edwards RH (1981) Human muscle function and fatigue. In: Porter R and Whelan J (ed)  
691 Human muscle fatigue: physiological mechanisms. Pitman, London, pp 1-8

692

693 Gerdle B, Karlsson S, Crenshaw AG, et al (2000) The influences of muscle fibre proportions  
694 and areas upon EMG during maximal dynamic knee extensions. *Eur J Appl Physiol Occup*  
695 *Physiol* 81:2–10. <https://doi.org/10.1007/PL00013792>

696

697 Graven-Nielsen T, Arendt-Nielsen L, Svensson P, Jensen TS (1997a) Quantification of local  
698 and referred muscle pain in humans after sequential i.m. injections of hypertonic saline. *Pain*  
699 69:111–117. [https://doi.org/10.1300/J094v05n01\\_04](https://doi.org/10.1300/J094v05n01_04)

700

701 Graven-Nielsen T, Arendt-Nielsen L, Svensson P, Jensen TS (1997b) Experimental muscle  
702 pain: a quantitative study of local and referred pain in humans following injection of  
703 hypertonic saline. *J Musculoskelet Pain* 5:46–69

704

705 Graven-Nielsen T, Lund H, Arendt-Nielsen L, et al (2002) Inhibition of maximal voluntary  
706 contraction force by experimental muscle pain: A centrally mediated mechanism. *Muscle and*  
707 *Nerve* 26:708–712. <https://doi.org/10.1002/mus.10225>

708

709 Graven-Nielsen T, McArdle A, Arendt-Nielsen L, et al (1997c) In vivo model of muscle  
710 pain: Quantification of intramuscular chemical, electrical and pressure changes associated  
711 with saline induced muscle pain in humans. *Pain* 69:137–143  
712

713 Graven-Nielsen T, Svensson P, Arendt-Nielsen L (1997d) Effects of experimental muscle  
714 pain on muscle activity and co-ordination during static and dynamic motor function.  
715 *Electroencephalogr Clin Neurophysiol - Electromyogr Mot Control* 105:156–164.  
716 [https://doi.org/10.1016/S0924-980X\(96\)96554-6](https://doi.org/10.1016/S0924-980X(96)96554-6)  
717

718 Henriksen M, Rosager S, Aaboe J, et al (2011) Experimental knee pain reduces muscle  
719 strength. *J Pain* 12:460–467. <https://doi.org/10.1016/j.jpain.2010.10.004>  
720

721 Hodges PW, Tucker K (2011) Moving differently in pain: A new theory to explain the  
722 adaptation to pain. *Pain* 152:S90–S98. <https://doi.org/10.1016/j.pain.2010.10.020>  
723

724 Hureau TJ, Weavil JC, Thurston TS, et al (2019) Pharmacological attenuation of group III/IV  
725 muscle afferents improves endurance performance when oxygen delivery to locomotor  
726 muscles is preserved. *J Appl Physiol* japplphysiol.00490.2019.  
727 <https://doi.org/10.1152/japplphysiol.00490.2019>  
728

729 Kennedy DS, Mcneil CJ, Gandevia SC, Taylor JL (2013) Firing of antagonist small-diameter  
730 muscle afferents reduces voluntary activation and torque of elbow flexors. *J Physiol*  
731 591:3591–3604. <https://doi.org/10.1113/jphysiol.2012.248559>  
732

733 Khan SI, McNeil CJ, Gandevia SC, Taylor JL (2011) Effect of experimental muscle pain on  
734 maximal voluntary activation of human biceps brachii muscle. *J Appl Physiol* 111:743–750.  
735 <https://doi.org/10.1152/jappphysiol.00603.2011>  
736

737 Laursen RJ, Graven-Nielsen T, Jensen TS, Arendt-Nielsen L (1999) The effect of differential  
738 and complete nerve block on experimental muscle pain in humans. *Muscle and Nerve*  
739 22:1564–1570  
740

741 Löllgen H, Graham T, Sjogaard G (1980) Muscle metabolites, force, and perceived exertion  
742 bicycling at varying pedal rates. *Med Sci Sports Exerc* 12:345–351.  
743 <https://doi.org/10.1249/00005768-198025000-00008>  
744

745 Lund JP, Donga R, Widmer CG, Stohler CS (1991) The pain-adaptation model: a discussion  
746 of the relationship between chronic musculoskeletal pain and motor activity. *Can J Physiol*  
747 *Pharmacol* 69:683–694  
748

749 Mauger AR (2013) Fatigue is a pain—the use of novel neurophysiological techniques to  
750 understand the fatigue-pain relationship. *Front Physiol* 4 MAY:1–4.  
751 <https://doi.org/10.3389/fphys.2013.00104>  
752

753 Mauger AR (2014) Factors affecting the regulation of pacing: current perspectives. *Open*  
754 *Access J Sport Med* 5:209–214. <https://doi.org/10.2147/OAJSM.S38599>  
755

756 Melzack R (1975) The McGill Pain Questionnaire: Major properties and scoring methods.  
757 *Pain* 1:277–299

758

759 Mense S (1993) Nociception from skeletal muscle in relation to clinical muscle pain. *Pain*

760 54:241–289. [https://doi.org/10.1016/0304-3959\(93\)90027-M](https://doi.org/10.1016/0304-3959(93)90027-M)

761

762 Micklewright D, St Clair Gibson A, Gladwell V, Al Salman A (2017) Development and

763 Validity of the Rating-of-Fatigue Scale. *Sport Med* 47:2375–2393.

764 <https://doi.org/10.1007/s40279-017-0711-5>

765

766 Motl RW, Gliottoni RC, Scott JA (2007) Self-Efficacy Correlates With Leg Muscle Pain

767 During Maximal and Submaximal Cycling Exercise. *J Pain* 8:583–587.

768 <https://doi.org/10.1016/j.jpain.2007.03.002>

769

770 Nicolò A, Sacchetti M, Girardi M, et al (2019) A comparison of different methods to analyse

771 data collected during time - to - exhaustion tests. *Sport Sci Health*.

772 <https://doi.org/10.1007/s11332-019-00585-7>

773

774 O'Connor PJ, Cook DB (1999) Exercise and Pain: The Neurobiology, Measurement, and

775 Laboratory Study of Pain in Relation to Exercise in Humans. *Exerc Sport Sci Rev* 27:119–

776 166

777

778 Olesen AE, Andresen T, Staahl C, Drewes AM (2012) Human Experimental Pain Models for

779 Assessing the Therapeutic Efficacy of Analgesic Drugs. *Pharmacol Rev* 64:722–779.

780 <https://doi.org/10.1124/pr.111.005447>.

781

782 Pageaux B, Angius L, Hopker JG, et al (2015) Central alterations of neuromuscular function  
783 and feedback from group III-IV muscle afferents following exhaustive high-intensity one-leg  
784 dynamic exercise. *Am J Physiol Integr Comp Physiol* 308:R1008–R1020.  
785 <https://doi.org/10.1152/ajpregu.00280.2014>  
786

787 Pollak KA, Swenson JD, Vanhaisma TA, et al (2014) Exogenously applied muscle  
788 metabolites synergistically evoke sensations of muscle fatigue and pain in human subjects.  
789 *Exp Physiol* 99: 368-380  
790

791 Raasch CC, Zajac FE, Ma B, Levine WS (1997) Muscle coordination of movement of  
792 maximum-speed pedaling. *J Biomech* 30:595–602  
793

794 Sasaki K, Neptune RR (2006) Differences in muscle function during walking and running at  
795 the same speed. *J Biomech* 39:2005–2013. <https://doi.org/10.1016/j.jbiomech.2005.06.019>  
796

797 Schmitz AK, Vierhaus M, Lohaus A (2013) Pain tolerance in children and adolescents: Sex  
798 differences and psychosocial influences on pain threshold and endurance. *Eur J Pain (United*  
799 *Kingdom)* 17:124–131. <https://doi.org/10.1002/j.1532-2149.2012.00169.x>  
800

801 Sherman JJ, LeResche L (2006) Does experimental pain response vary across the menstrual  
802 cycle? A methodological review. *Am J Physiol Integr Comp Physiol* 291:R245–R256.  
803 <https://doi.org/10.1152/ajpregu.00920.2005>  
804

805 Sidhu SK, Weavil JC, Thurston TS, et al (2018) Fatigue-related group III/IV muscle afferent  
806 feedback facilitates intracortical inhibition during locomotor exercise. *J Physiol* 596:4789–  
807 4801. <https://doi.org/10.1113/JP276460>

808

809 Staahl C, Drewes AM (2004) Experimental Human Pain Models : A Review of Standardised  
810 Methods for Preclinical Testing of Analgesics. 97–111

811

812 Tucker KJ, Hodges PW (2010) Changes in motor unit recruitment strategy during pain alters  
813 force direction. *Eur J Pain* 14:932–938. <https://doi.org/10.1016/j.ejpain.2010.03.006>

814

815 Watson D, Clark LA, Tellegen A (1988) Development and validation of brief measures of  
816 positive and negative affect: The PANAS scales. *J Pers Soc Psychol* 54:1063–1070.

817 <https://doi.org/10.1037/0022-3514.54.6.1063>

818

819

820

821

822

823

824